

Evaluation of mRNA-1273 Covid-19 Vaccine in Children

New England Journal of Medicine

386, 2011-2023

DOI: [10.1056/nejmoa2203315](https://doi.org/10.1056/nejmoa2203315)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Boosting immunity to Omicron. <i>Nature Medicine</i> , 2022, 28, 445-446.	30.7	29
2	La pagina gialla. <i>Medico E Bambino</i> , 2022, 41, 281-282.	0.1	0
3	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	5.5	7
4	The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6â€“14 years: a cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 619-619.	1.7	19
5	Increasing children's global access to COVID-19 vaccines. <i>Lancet, The</i> , 2022, 399, 2171-2173.	13.7	1
6	Routine <scp>SARSâ€“CoV</scp>â€“2 vaccination for all children*. <i>Immunological Reviews</i> , 2022, 309, 90-96.	6.0	7
7	SARS-CoV-2 Vaccination: What Can We Expect Now?. <i>Vaccines</i> , 2022, 10, 1093.	4.4	0
8	SARS-CoV-2 vaccines in children and adolescents: Can immunization prevent hospitalization?. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 891-895.	1.4	6
10	Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience. <i>Vaccines</i> , 2022, 10, 1224.	4.4	5
11	COVID-19 and Acute Neurologic Complications in Children. <i>Pediatrics</i> , 2022, 150, .	2.1	34
13	Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review. <i>Children</i> , 2022, 9, 1467.	1.5	3
14	New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 775-799.	6.7	31
16	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	1.1	0
17	Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. <i>Clinical Infectious Diseases</i> , 2023, 76, 271-280.	5.8	3
18	Real Life Evidence From the Use of COVID-19 mRNA Vaccines in Pediatric Populations. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	2.0	1
19	Answers to common questions about COVIDâ€“19 vaccines in children with cancer. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	1.5	3
20	Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5â€“11Âyears and comparison with individuals aged 12â€“15Âyears: an observational and historical cohort study. <i>European Journal of Pediatrics</i> , 2023, 182, 123-133.	2.7	5
21	Long COVID: An inevitable sequela of SARS-CoV-2 infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 1-9.	3.1	42

#	ARTICLE	IF	CITATIONS
22	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	4.4	12
23	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	7.0	77
24	Relationship between Anti-Spike Antibodies and Risk of SARS-CoV-2 Infection in Infants Born to COVID-19 Vaccinated Mothers. <i>Vaccines</i> , 2022, 10, 1696.	4.4	13
25	Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5â€“11 years: Results from an active pharmacovigilance study in central Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	8
26	Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. <i>New England Journal of Medicine</i> , 2022, 387, 1673-1687.	27.0	63
27	Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
28	Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5â€“11 Years. <i>Vaccines</i> , 2022, 10, 1954.	4.4	3
29	Case report: Myocarditis with nonsustained ventricular tachycardia following COVID-19 mRNA vaccination in a female adolescent. <i>Frontiers in Pediatrics</i> , 0, 10, .	1.9	2
30	COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review. <i>Vaccines</i> , 2022, 10, 2039.	4.4	2
31	The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
32	COVID-19 vaccination in children: a public health priority. <i>Jornal De Pediatria</i> , 2022, , .	2.0	1
33	A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVIDâ€“19 mRNA vaccination. <i>British Journal of Clinical Pharmacology</i> , 0, , .	2.4	4
36	Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2023, 11, 87.	4.4	5
37	Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years. <i>JAMA Pediatrics</i> , 2023, 177, 384.	6.2	27
40	COVID-19 Vaccination in Pediatrics: Was It Valuable and Successful?. <i>Vaccines</i> , 2023, 11, 214.	4.4	2
41	Construction and immunogenicity of an mRNA vaccine against chikungunya virus. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
42	Efficacy of SARS-CoV-2 vaccines and the doseâ€“response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	7.3	46
43	Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5â€“15 years in Australia. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 31, 100684.	2.9	1

#	ARTICLE	IF	CITATIONS
44	Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis. <i>World Journal of Pediatrics</i> , 2023, 19, 1041-1054.	1.8	8
45	Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study. <i>Vaccines</i> , 2023, 11, 401.	4.4	4
46	Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. <i>The Lancet Child and Adolescent Health</i> , 2023, 7, 269-279.	5.6	6
47	Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. <i>Vaccines</i> , 2023, 11, 509.	4.4	0
49	Challenges and Recent Advancements in COVID-19 Vaccines. <i>Microorganisms</i> , 2023, 11, 787.	3.6	1
50	Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years. <i>World Journal of Pediatrics</i> , 2023, 19, 949-960.	1.8	2
52	Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis. <i>The Lancet Child and Adolescent Health</i> , 2023, 7, 379-391.	5.6	19
53	Diversity and inclusion in clinical trials: Evolution throughout the development of an mRNA COVID-19 vaccine. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	3
54	Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	1
55	Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review. <i>Expert Review of Vaccines</i> , 2023, 22, 393-409.	4.4	3
56	Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT. , 2023, 1, .		1
57	Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 1257-1265.	9.1	9
59	Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	1
60	Impact of congenital heart disease on outcomes among pediatric patients hospitalized for COVID-19 infection. <i>BMC Pediatrics</i> , 2023, 23, .	1.7	0
61	Impact of SARS-CoV-2 Infection in Children with Asthma and Impact of COVID-19 Vaccination: Current Evidence and Review of the Literature. <i>Microorganisms</i> , 2023, 11, 1745.	3.6	3
62	mRNA vaccines against respiratory viruses. <i>Current Opinion in Infectious Diseases</i> , 2023, 36, 385-393.	3.1	7
63	Effectiveness of COVID-19 Vaccine Doses in Children: Case of Lake Region Economic Bloc-Kenya. <i>Open Journal of Modelling and Simulation</i> , 2023, 11, 88-97.	1.3	0
64	Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India. <i>JAMA Pediatrics</i> , 0, , .	6.2	1

#	ARTICLE	IF	CITATIONS
65	The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. <i>Pediatric Rheumatology</i> , 2023, 21, .	2.1	4
66	Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3â€“18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study). <i>EClinicalMedicine</i> , 2023, 63, 102160.	7.1	0
67	Dilemmas and options for COVID-19 vaccination in children. <i>Italian Journal of Pediatrics</i> , 2023, 49, .	2.6	0
68	Successful treatment of fulminant myocarditis due to COVID-19 in a 5-year-old girl. <i>Journal of Cardiology Cases</i> , 2023, , .	0.5	0
69	Multisystem Inflammatory Syndrome in Children Following COVID-19 Vaccination: A Sex-Stratified Analysis of the VAERS Database Using Brighton Collaboration Criteria. <i>Pharmaceuticals</i> , 2023, 16, 1231.	3.8	0
70	mRNA vaccines in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	9
71	Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile. <i>Vaccines</i> , 2023, 11, 1526.	4.4	0
72	Protection of COVID-19 vaccine in general and special population. , 2023, , .		0
73	Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine. <i>Expert Review of Vaccines</i> , 2023, 22, 801-812.	4.4	1
75	Factors associated with COVID-19 vaccination in young children. <i>Canadian Journal of Public Health</i> , 2024, 115, 40-52.	2.3	0
76	Humoral immune response characteristics of the elderly, children and pregnant women after XBB infection. <i>Journal of Infection</i> , 2023, 87, e96-e99.	3.3	2
77	Side effects of vaccines. <i>Side Effects of Drugs Annual</i> , 2023, , .	0.6	0
78	Emerging and re-emerging pediatric viral diseases: a continuing global challenge. <i>Pediatric Research</i> , 2024, 95, 480-487.	2.3	2
79	Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review. <i>Medicina (Lithuania)</i> , 2023, 59, 2027.	2.0	0
80	Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to nonâ€“vaccine-associated myocarditis within the prospective multicenter registryâ€”âœMYKKEâœ. <i>American Heart Journal</i> , 2024, 267, 101-115.	2.7	0
81	Increasing COVID-19 Immunization Rates through a Vaccination Program for Hospitalized Children. <i>Pediatric Quality & Safety</i> , 2023, 8, e704.	0.8	1
83	A pilot recruitment strategy to enhance ethical and equitable access to Covid-19 pediatric vaccine trials. <i>Clinical Trials</i> , 0, , .	1.6	0
84	COVID-19 Vaccines in Children. <i>Journal of Clinical Medicine</i> , 2024, 13, 87.	2.4	0

#	ARTICLE	IF	CITATIONS
85	Comparative immunogenicity and safety of SpikoGen [®] , a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial. <i>International Immunopharmacology</i> , 2024, 127, 111436.	3.8	0
86	Development of COVID-19 vaccine policy â€” United States, 2020â€”2023. <i>Vaccine</i> , 2023, , .	3.8	2
87	Vaccination against COVID-19 â€” risks and benefits in children. <i>European Journal of Pediatrics</i> , 2024, 183, 1107-1112.	2.7	1
88	The new frontier: Clinical consequences of long COVID. <i>Journal of Precision Respiratory Medicine</i> , 2023, 6, 2-9.	0.1	1
89	Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study. <i>Vaccine</i> , 2024, 42, 1145-1153.	3.8	0
90	Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials. <i>Vaccines</i> , 2024, 12, 130.	4.4	0
91	Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination. <i>Nature Communications</i> , 2024, 15, .	12.8	0
92	Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus. <i>Lupus</i> , 2024, 33, 450-461.	1.6	0
93	SARS-CoV-2, COVID-19, and Children: Myths and Evidence. , 2023, , 503-520.		0
94	Willingness and understanding of the safety and effectiveness of <scp>COVID</scp>â€”19 vaccines in young children: a <scp>crossâ€”sectional</scp> study among parents in Malaysia. <i>Journal of Pharmacy Practice and Research</i> , 2024, 54, 158-169.	0.8	0
95	Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. <i>BMC Infectious Diseases</i> , 2024, 24, .	2.9	0
96	Anti-SARS-CoV-2 Vaccination and PIMS-TSâ€”Friends or Foe? Case Reports and Literature Review. <i>Vaccines</i> , 2024, 12, 278.	4.4	0
98	The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children. <i>Lancet Infectious Diseases</i> , The, 2024, , .	9.1	0
99	Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2024, , .	9.1	0